Respiratory Syncytial Virus (RSV) is the main cause of respiratory infections in the first
years of life. Preterm infants and those affected by broncopulmonary dysplasia (BPD) represent
the categories at highest risk of severe RSV infections. Palivizumab is a monoclonal
RSV antibody recently proposed for the prevention of RSV infections in at risk infants. The
Authors discuss the results of controlled trials. The cost/benefit profile of the preventive use
of palivizumab is not favorable and more studies are needed for evaluating the preventive
efficacy of palivizumab on the RSV related morbidity and mortality.